The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Thalidomide in the treatment of lepra reactions
Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 533
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Rüegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., & Lejeune, F. J. (1998) · Nature Medicine · doi:10.1038/nm0498-408 · Cited by 450
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas
Fine, H. A., Figg, W. D., Jaeckle, K., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A., Black, P. M., Kaplan, R., Pluda, J. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.708 · Cited by 423
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A. C., Miguel, C. P., Viana, S. M., & Sarno, E. N. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.2.408 · Cited by 366
Tumour necrosis factor α: a potential target for the therapy of solid tumours
Szlosarek, P. W., & Balkwill, F. R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01196-3 · Cited by 355
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Muller, G. W., Chen, R., Huang, S.-Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. I. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1004 · Cited by 338
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Burley, D. M., & Lenz, W. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91217-5 · Cited by 324
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Self-citationImmunomodulatory drug costimulates T cells via the B7-CD28 pathway
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., et al. (2004) · Blood · doi:10.1182/blood-2003-02-0361 · Cited by 289
Taming TNF: strategies to restrain this proinflammatory cytokine
Eigler, A., Sinha, B., Hartmann, G., & Endres, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01118-3 · Cited by 284
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242
Raje, N., & Anderson, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412110 · Cited by 230
Schafer, P. H., Gandhi, A. K., Loveland, M. A., Chen, R. S., Man, H.-W., Schnetkamp, P. P. M., Wolbring, G., Govinda, S., Corral, L. G., Payvandi, F., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048496 · Cited by 182
Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 162
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Iyer, C. G. S., Languillon, J., Ramanujam, K., Tarabini-castellani, G., Aguas, J. T. D. L., Lm, B., Uemura, K., Domínguez, M. S. C., & Sundaresan, T. (1971) · Europe PMC (PubMed Central) · Cited by 155
Marriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155
Self-citationBartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 143
Self-citationNeuropathy After Intake of Thalidomide (Distaval)
Fullerton, P. M., & Kremer, M. (1961) · BMJ · doi:10.1136/bmj.2.5256.855 · Cited by 133
Thalidomide as an emerging immunotherapeutic agent
Marriott, J. B., Muller, G. W., & Dalgleish, A. G. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01531-5 · Cited by 123
Self-citationThe treatment of advanced renal cell cancer with high-dose oral thalidomide
Stebbing, J., Benson, C., Eisen, T. G., Pyle, L., Smalley, K. S. M., Bridle, H., Mak, I., Sapunar, F. J., A’Hern, R., & Gore, M. E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2025 · Cited by 109
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G. W., Shire, M. G., Stirling, D., & Dalgleish, A. G. (1998) · PubMed · Cited by 102
Self-citationThalidomide a promising new treatment for rheumatoid arthritis
Gutiérrez‐Rodríguez, O. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780271006 · Cited by 96
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
Kumar, S. K., Witzig, T. E., Dispenzieri, A. A., Lacy, M. Q., Wellik, L. E., Fonseca, R., Lust, J. A., Gertz, M. A., Kyle, R. A., Greipp, P. R., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403285 · Cited by 96
Thalidomide in Crohn's disease
Wettstein, A. R., Meagher, A. P., & Meagher, A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)64206-7 · Cited by 96
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G. W., Shire, M. G., Stirling, D., & Dalgleish, A. G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.4236 · Cited by 89
Self-citationS-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch, S., Rogers, M. S., LeBlanc, R., Birsner, A. E., Shah, J. H., Treston, A. M., Anderson, K. C., & D’Amato, R. J. (2002) · PubMed · Cited by 88
Thalidomide as an anti‐cancer agent
Kumar, S. K., Witzig, T. E., & Rajkumar, S. V. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00184.x · Cited by 72
Thalidomide on the comeback trail
Hales, B. F. (1999) · Nature Medicine · doi:10.1038/8371 · Cited by 68
Thalidomide Inhibits Tumor Necrosis Factor-α Production and Antigen Presentation by Langerhans Cells
Deng, L., Ding, W., & Granstein, R. D. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12565.x · Cited by 66
Immunotherapeutic and antitumour potential of thalidomide analogues
Marriott, J. B., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.675 · Cited by 52
Self-citationA developmental model for thalidomide defects
Tabin, C. J. (1998) · Nature · doi:10.1038/24516 · Cited by 51
Thalidomide: a new anticancer drug?
Fanelli, M., Sarmiento, R., Gattuso, D., Carillio, G., Capaccetti, B., Vacca, A., Roccaro, A. M., & Gasparini, G. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1211 · Cited by 42
Thalidomide and Its Derivatives: New Promise for Multiple Myeloma
Weber, D. (2003) · Cancer Control · doi:10.1177/107327480301000504 · Cited by 42
Effect of Thalidomide on Chemokine Production by Human Microglia
Lokensgard, J. R., Hu, S., van Fenema, E. M., Sheng, W. S., & Peterson, P. K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315754 · Cited by 35
McCarthy, D., Kanfer, E., & Barrett, A. J. (1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90089-9 · Cited by 27
Current status of thalidomide and its role in the treatment of metastatic prostate cancer
Macpherson, G. R., FRANKS, M. E., Tomoaia‐Cotisel, A., Ando, Y., Price, D. K., & Figg, W. D. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00064-7 · Cited by 24
Cited by
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Ribosomopathies: human disorders of ribosome dysfunction
Narla, A., & Ebert, B. L. (2010) · Blood · doi:10.1182/blood-2009-10-178129 · Cited by 809
Metadata
- Authors
- Bartlett, J. B., Dredge, K., & Dalgleish, A. G.
- Venue
- Nature Reviews Cancer
- Published
- 2004-04
- Volume
- 4
- Issue
- 4
- Pages
- 314-322
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1597238753
- Cited by
- 809
- References
- 53
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.